The biopreservation industry is driven by several aspects that make it important in healthcare and life sciences. The growing need for biopreservation methods to store and transfer biological samples, cells, tissues, and organs is a major driver. Effective preservation technologies are needed as biomedical research and regenerative medicine improve, propelling the biopreservation industry.
Advances in technology shape the biopreservation business. Preservation, cryopreservation, and storage improvements improve biopreservation efficiency and reliability. Biological materials can be used in research and therapeutic contexts thanks to vitrification and controlled-rate freezing.
The biopreservation market grows as the biopharmaceutical sector globalizes. Standardized and dependable biopreservation methods are needed as worldwide R&D collaborates. Biological samples must be stored and transported internationally for global research, clinical trials, and cell treatments.
Key industry players and market competition affect the Biopreservation market. Research, strategic partnerships, and new products affect market dynamics. Competition drives biopreservation technology developments, giving researchers and healthcare providers a variety of biological material preservation options.
Biopreservation is affected by customized medicine and cell-based therapy. The growing emphasis on personalized therapy necessitates the storage and preservation of patient-specific cells and tissues. Advanced biopreservation approaches are needed to develop and execute individualized medicinal interventions.
In biopreservation, regulatory compliance is also important. For cell treatments and transplantation, strict requirements protect the safety, integrity, and traceability of preserved biological resources. These guidelines increase biopreservation method confidence and encourage their wider use in healthcare.
Increasing interest in stem cell research and regenerative medicine drives biopreservation options. Stem cell storage and banking are crucial as regenerative medicine grows. Long-term stem cell storage using biopreservation methods like cryopreservation allows tissue engineering and cell-based therapy research and treatment.
COVID-19 has highlighted the necessity of biopreservation in vaccine development and delivery. Safe preservation procedures are essential for storing and transporting vaccinations and viral vectors. Global immunization initiatives have relied on biopreservation technology to maintain vaccine stability and efficacy.
Healthcare infrastructure and biotechnology investments influence biopreservation. Biobanks, cell treatment facilities, and research institutions promote sophisticated biopreservation methods. The biopreservation market grows in biotechnology and life sciences-focused countries due to modern storage and preservation facilities.
Patient awareness and advocacy boost the biopreservation sector, notably for fertility preservation. Interest in fertility preservation alternatives like oocyte and sperm banking promotes need for dependable biopreservation methods. These technologies enable infertile people to save reproductive tissue for future use, demonstrating biopreservation's social influence."
Report Attribute/Metric | Details |
---|---|
Growth Rate |   11.5% (2023–2032 |
The Biopreservation market is expected to reach USD 6.01 Billion at a CAGR 11.5% during the forecast period 2023-2032. Biopreservation is a use of natural flora and its antibacterial products to preserve biological material. Biopreservation is playing an important role in healthcare and food industry to preserve the biological material or food product for a long time.
The increasing expenditure on healthcare, growing demand for stem cell preservation and awareness about its use with regards to treatment of diseases are expected to drive the growth of the market. Moreover, increasing awareness about personalized medicines and its applications are contributing to the growth of the biopreservation market. According to the US Food and Drug Administration (FDA), The department has approved 16 personalized medicines in the year 2017, which accounts for 20% of total drug approvals.
The rising high price of biopreservation instruments and its maintenance, stability issues related to the specimen and lack of skilled personnel for handling the biopreservation process may hamper the growth of the market during the assessment period.
The biopreservation market has been segmented on the basis of product, biospecimen, and application.
On the basis of product, the market has been classified as media and equipment. The media subsegment has been further divided into nutrient media, sera, and growth factors and supplements. The equipment segment has been further divided into temperature control systems, accessories, alarms & monitoring systems, incubators, centrifuges, and other equipment. The temperature control systems segment has been further classified as freezers, cryogenic storage systems, thawing equipment, and refrigerators.
The biospecimen segment has been divided into human tissue samples, organs, stem cells, and other biospecimens.
The market, by source, has been segmented into regenerative medicine, biobanking, and drug discovery. On basis of regenerative medicine, the market has been divided into cell therapy, gene therapy, and others. Biobanking segment includes human egg, human sperm, and veterinary IVF.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The biopreservation market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The biopreservation market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market in the Middle East & Africa has been segmented into the Middle East and Africa.
The Americas are likely to dominate the global biopreservation market owing to the adoption of advanced technology, increasing spending on healthcare R&D, the presence of a well-established healthcare system, and increasing in-house sample storage in hospitals and research institutes. Moreover, presence and recent merger and acquisition activities by market players in the region are contributing to the growth of the market. For instance, in 2017, Cesca Therapeutics Inc. has acquired Sacramento’s SynGen Inc. for USD 1 million with this acquisition company has managed to add cell separation and cord blood processing products in their portfolio.
The European market is expected to be the second-largest biopreservation market. The market growth in this region can be attributed to the increasing number of births and with-it continuous increase in demand for umbilical cord preservation. According to the European Commission, in the year 2016 more than 5.1 million babies were born in Europe. Moreover, a growing number of sperm and egg banks is contributing to the growth of the market in this region.
Asia-Pacific is expected to be the fastest-growing biopreservation market during the forecast period owing to the increasing population in the region, increasing awareness about stem cell preservation and continuous development in the healthcare sector due to government funding.
The market in the Middle East & Africa is expected to account for the smallest share of the global biopreservation market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
Intended Audience
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)